Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study.
Saved in:
| Title: | Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S‐1 for neoadjuvant therapy of locally advanced gastric cancer with HER2‐overexpressing: Preliminary results of a prospective, single‐arm, phase II study. |
|---|---|
| Authors: | Wang, Longgang1 (AUTHOR), Liu, Bing1 (AUTHOR), Liu, Luguang1 (AUTHOR), Liu, Liqing1 (AUTHOR), Li, Rong2 (AUTHOR), Han, Shumei3 (AUTHOR), Sun, Xu1 (AUTHOR), Bi, Bo1 (AUTHOR), Sun, Yuanlin1 (AUTHOR), Sun, Dong1 (AUTHOR) dsun@email.sdfmu.edu.cn, Chai, Jie1 (AUTHOR) jchai@sdfmu.edu.cn |
| Source: | Clinical & Translational Medicine. May2026, Vol. 16 Issue 5, p1-18. 18p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20011326 |
|---|---|
| DOI: | 10.1002/ctm2.70679 |
